Zannad F, McMurray JJ, Drexler H, et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure ( EMPHASIS – HF ). Eur J Heart Fail 2010 12: 617 -.
The purpose of the EMPHASIS – HF trial was to explore the effects of adding eplerenone, a type of mineralocorticoid antagonist, to evidence-based therapy in patients with systolic heart failure and only mild symptoms (i.e.
LVEF<35% and NYHA class II symptoms). The findings demonstrated that eplerenone significantly reduces the risk of death from ...1/29/2016 · Estudio PARADIGM- HF: LCZ696 en Insuficiencia Cardiaca 1. A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray, Akshay S. Desai, Jianjian Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, Victor C. Shi, Scott D. Solomon, Karl ...En el estudio EMPHASIS-HF han participado, aproximadamente, 3.100 pacientes y se iba a seguir incluyendo a pacientes hasta que se informasen un total de 813 eventos que cumplieran los objetivos de valoración primarios. El profesor Faiez Zannad, representante del Inserm y de la Universidad de Nancy de Francia y co-presidente del ESC, ha ...8/24/2015 · MERIT- HF established the survival benefit of extended-release metoprolol among patients with HFrEF. It was joined by CIBIS-II (1999) and COPERNICUS (2002), which demonstrated mortality benefit in a similar population with bisoprolol and carvedilol, respectively. Guidelines. AHA/ACCF Heart Failure Guidelines (2013, adapted), The EMPHASIS-HF trial: Eplerenone in mild systolic heart ...PIONEER-HF - Wiki Journal Club, MERIT-HF - Wiki Journal Club
